Mapp Biopharmaceutical, Inc. — Federal Contractor Profile
MAPP BIOPHARMACEUTICAL, INC. Secures $591 Million in Federal Contracts
Contractor Overview
Total Contract Value: $7,982,921,941 ($8.0B)
Total Awards: 54
Company Profile
MAPP BIOPHARMACEUTICAL, INC. appears to be a significant player in the federal contracting landscape, primarily focused on the pharmaceutical and biopharmaceutical sectors. With a substantial total contract value of $591.3 million across just four contracts, the company demonstrates a capacity for handling large-scale, high-value government projects. The average contract size of nearly $148 million suggests that MAPP BIOPHARMACEUTICAL, INC. likely engages in complex research, development, manufacturing, or supply chain management of critical medical products or services. The absence of specific agency clients listed in the provided data makes it difficult to pinpoint their primary government partners, but the nature of their business strongly suggests engagements with agencies like the Department of Health and Human Services (HHS), particularly the Food and Drug Administration (FDA) or the National Institutes of Health (NIH), and potentially the Department of Defense (DoD) for medical readiness or research initiatives. The limited number of contracts, coupled with their high average value, indicates a strategy focused on securing major, long-term awards rather than a high volume of smaller task orders. This approach often involves highly specialized expertise and a proven ability to meet stringent government requirements. Without detailed contract descriptions, it's challenging to ascertain their win patterns (competitive vs. sole-source) or specific track records. However, the substantial financial commitment from the government implies a level of trust and demonstrated capability in delivering essential biopharmaceutical solutions. Their contract patterns suggest a business model centered on securing and executing large, impactful government programs, likely requiring significant scientific and logistical prowess.
Specializations
- Biopharmaceutical Research and Development
- Pharmaceutical Manufacturing
- Medical Supply Chain Management
- Clinical Trials Support
- Drug Discovery and Innovation
- Biotechnology Solutions
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: Undetermined
Agency Concentration: Undetermined
Growth Trajectory: Undetermined
Competitive Position
Given the limited data, MAPP BIOPHARMACEUTICAL, INC.'s competitive position is difficult to definitively assess. However, the substantial value of their contracts suggests they are capable of competing for and winning significant government awards in the biopharmaceutical space. Their ability to secure such large contracts implies they possess specialized expertise and capabilities that are in demand by federal agencies. They may be a niche specialist focusing on high-value, complex projects or a more established provider within specific biopharmaceutical domains.
Value to Taxpayers
The significant value of contracts awarded to MAPP BIOPHARMACEUTICAL, INC. suggests the government perceives substantial value in their specialized biopharmaceutical services. The large average contract size indicates the potential for economies of scale and the delivery of critical, complex solutions. However, without more information on contract performance, competitive bidding history, and cost-effectiveness, a definitive assessment of value to taxpayers is challenging. The government's investment implies a need for their specific capabilities, but ongoing oversight would be crucial to ensure optimal value.
Agency Relationships
The provided data does not specify MAPP BIOPHARMACEUTICAL, INC.'s top agency clients. However, companies specializing in biopharmaceuticals typically work with agencies such as the Department of Health and Human Services (HHS) for public health initiatives and research, and potentially the Department of Defense (DoD) for medical countermeasures or research. Without this information, it's impossible to assess dependency risks.
Red Flags
- Lack of detailed contract information makes it impossible to assess performance or win patterns.
- Absence of specified top agency clients raises questions about the breadth and depth of their government engagement.
Green Flags
- Secured a substantial total contract value, indicating significant government trust and demand for their services.
- High average contract size suggests the ability to manage and execute large, complex projects.
Key Contracts
MAPP BIOPHARMACEUTICAL, INC. has been awarded a total of four government contracts valued at $591.3 million, with an average contract size of approximately $147.8 million. This significant financial commitment from the federal government underscores the company's role in providing high-value biopharmaceutical products or services. The sheer scale of these contracts suggests that MAPP BIOPHARMACEUTICAL, INC. is likely involved in critical areas such as the research and development of new pharmaceuticals, large-scale manufacturing of essential medicines, or the management of complex biopharmaceutical supply chains. The average contract value points towards substantial, long-term engagements that require deep scientific expertise, robust quality control, and significant operational capacity. While specific contract details and agency clients are not provided, such large awards are typically associated with agencies like the Department of Health and Human Services (HHS) for public health needs or the Department of Defense (DoD) for medical readiness. The limited number of contracts, combined with their high value, indicates a strategic focus on securing major program awards rather than numerous smaller task orders, suggesting a business model centered on delivering comprehensive, impactful biopharmaceutical solutions to the government.
Frequently Asked Questions
What does MAPP BIOPHARMACEUTICAL, INC. do for the government?
MAPP BIOPHARMACEUTICAL, INC. appears to specialize in the biopharmaceutical sector, undertaking large-scale government projects. Based on the substantial contract values, their work likely involves critical areas such as the research and development of new drugs, manufacturing of essential pharmaceuticals, or managing complex biopharmaceutical supply chains. These services are vital for public health initiatives, medical research, and potentially national security needs related to medical countermeasures.
How much taxpayer money does MAPP BIOPHARMACEUTICAL, INC. receive?
MAPP BIOPHARMACEUTICAL, INC. has received a total of $591.3 million across four government contracts. The average value of these contracts is approximately $147.8 million, indicating significant financial commitments from federal agencies for their specialized biopharmaceutical services.
Is MAPP BIOPHARMACEUTICAL, INC. good value for taxpayer money?
Assessing the value MAPP BIOPHARMACEUTICAL, INC. provides to taxpayers is difficult without more data. The government's substantial investment suggests a perceived need for their specialized biopharmaceutical capabilities. However, a full evaluation would require examining contract performance metrics, adherence to budgets, and competitive bidding history to ensure efficiency and effectiveness.
How does MAPP BIOPHARMACEUTICAL, INC. win its contracts?
The provided data does not specify whether MAPP BIOPHARMACEUTICAL, INC. wins contracts through competitive bidding or sole-source awards. However, the high average contract value suggests they are capable of securing large, significant government contracts, which often involves a rigorous selection process, whether competitive or through specialized qualifications.
What agencies use MAPP BIOPHARMACEUTICAL, INC. most?
The specific government agencies that contract with MAPP BIOPHARMACEUTICAL, INC. are not detailed in the provided information. Typically, companies in this sector collaborate with agencies like the Department of Health and Human Services (HHS) for health-related programs and research, or the Department of Defense (DoD) for medical supplies and research.